Education
About Us
Working with TipRanks
Follow Us
Charles N II York Insider Profile
4 Followers
Charles N II York, CFO and VP at Spyre Therapeutics, holds 240.13K shares in Day One Biopharmaceuticals (Ticker: DAWN), holds 34.79K shares in Spyre Therapeutics (Ticker: SYRE).
Charles N II York has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Charles N II York holds in companies
Most Profitable Insider Trade
The most profitable trade made by Charles N II York
Charles N II York's Trading History
Spyre Therapeutics
Dec 05, 2017
CFO and VP
Uninformative Buy
21.44K
$678.00K
Day One Biopharmaceuticals
Nov 19, 2024
COO, CFO AND SECRETARY
Uninformative Buy
101.79K
$2.08M
List of latest transactions for each holding click on a transaction to see Charles N II York's performance on stock
You May Also Like
Charles N II York insider profile FAQ
What is the percentage of profitable transactions made by Charles N II York?
The percentage of profitable transactions made by Charles N II York is ―.
What is the average return per transaction made by Charles N II York?
The average return per transaction made by Charles N II York is ―.
What stocks does Charles N II York hold?
Charles N II York holds: SYRE, DAWN stocks.
What was Charles N II York’s latest transaction?
Charles N II York latest transaction was an Uninformative Buy of $101.79K.
What was Charles N II York's most profitable transaction?
Charles N II York’s most profitable transaction was an Informative Buy of SYRE stock on December 5, 2017. The return on the trade was 71.00%.
What is Charles N II York's role in Spyre Therapeutics?
Charles N II York's role in Spyre Therapeutics is CFO and VP.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.